286 related articles for article (PubMed ID: 26854747)
1. DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors.
Harris PA; King BW; Bandyopadhyay D; Berger SB; Campobasso N; Capriotti CA; Cox JA; Dare L; Dong X; Finger JN; Grady LC; Hoffman SJ; Jeong JU; Kang J; Kasparcova V; Lakdawala AS; Lehr R; McNulty DE; Nagilla R; Ouellette MT; Pao CS; Rendina AR; Schaeffer MC; Summerfield JD; Swift BA; Totoritis RD; Ward P; Zhang A; Zhang D; Marquis RW; Bertin J; Gough PJ
J Med Chem; 2016 Mar; 59(5):2163-78. PubMed ID: 26854747
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.
Harris PA; Berger SB; Jeong JU; Nagilla R; Bandyopadhyay D; Campobasso N; Capriotti CA; Cox JA; Dare L; Dong X; Eidam PM; Finger JN; Hoffman SJ; Kang J; Kasparcova V; King BW; Lehr R; Lan Y; Leister LK; Lich JD; MacDonald TT; Miller NA; Ouellette MT; Pao CS; Rahman A; Reilly MA; Rendina AR; Rivera EJ; Schaeffer MC; Sehon CA; Singhaus RR; Sun HH; Swift BA; Totoritis RD; Vossenkämper A; Ward P; Wisnoski DD; Zhang D; Marquis RW; Gough PJ; Bertin J
J Med Chem; 2017 Feb; 60(4):1247-1261. PubMed ID: 28151659
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
Im D; Jung K; Yang S; Aman W; Hah JM
Eur J Med Chem; 2015 Sep; 102():600-10. PubMed ID: 26318067
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K).
Castanedo GM; Blaquiere N; Beresini M; Bravo B; Brightbill H; Chen J; Cui HF; Eigenbrot C; Everett C; Feng J; Godemann R; Gogol E; Hymowitz S; Johnson A; Kayagaki N; Kohli PB; Knüppel K; Kraemer J; Krüger S; Loke P; McEwan P; Montalbetti C; Roberts DA; Smith M; Steinbacher S; Sujatha-Bhaskar S; Takahashi R; Wang X; Wu LC; Zhang Y; Staben ST
J Med Chem; 2017 Jan; 60(2):627-640. PubMed ID: 28005357
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of RIP1 inhibition by necrostatins.
Xie T; Peng W; Liu Y; Yan C; Maki J; Degterev A; Yuan J; Shi Y
Structure; 2013 Mar; 21(3):493-9. PubMed ID: 23473668
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Biological Evaluation of 1-Benzyl-1H-pyrazole Derivatives as Receptor Interacting Protein 1 Kinase Inhibitors.
Zou C; Xiong Y; Huang LY; Song CL; Wu XA; Li LL; Yang SY
Chem Biol Drug Des; 2016 Apr; 87(4):569-74. PubMed ID: 26577270
[TBL] [Abstract][Full Text] [Related]
7. 6,7-Dihydrobenzo[f]benzo[4,5]imidazo[1,2-d][1,4]oxazepine derivatives as selective inhibitors of PI3Kα.
Yin Y; Zhang YQ; Jin B; Sha S; Wu X; Sangani CB; Wang SF; Qiao F; Lu AM; Lv PC; Zhu HL
Bioorg Med Chem; 2015 Mar; 23(6):1231-40. PubMed ID: 25693787
[TBL] [Abstract][Full Text] [Related]
8. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
[TBL] [Abstract][Full Text] [Related]
9.
Zhang H; Xu L; Qin X; Chen X; Cong H; Hu L; Chen L; Miao Z; Zhang W; Cai Z; Zhuang C
J Med Chem; 2019 Jul; 62(14):6665-6681. PubMed ID: 31095385
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 H-pyrazolo[3,4- c]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure-Kinetic Relationships.
Yoshikawa M; Saitoh M; Katoh T; Seki T; Bigi SV; Shimizu Y; Ishii T; Okai T; Kuno M; Hattori H; Watanabe E; Saikatendu KS; Zou H; Nakakariya M; Tatamiya T; Nakada Y; Yogo T
J Med Chem; 2018 Mar; 61(6):2384-2409. PubMed ID: 29485864
[TBL] [Abstract][Full Text] [Related]
11. Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.
Ren L; Grina J; Moreno D; Blake JF; Gaudino JJ; Garrey R; Metcalf AT; Burkard M; Martinson M; Rasor K; Chen H; Dean B; Gould SE; Pacheco P; Shahidi-Latham S; Yin J; West K; Wang W; Moffat JG; Schwarz JB
J Med Chem; 2015 Feb; 58(4):1976-91. PubMed ID: 25603482
[TBL] [Abstract][Full Text] [Related]
12. Use of RIP1 Kinase Small-Molecule Inhibitors in Studying Necroptosis.
Beal AM; Bertin J; Reilly MA
Methods Mol Biol; 2018; 1857():109-124. PubMed ID: 30136235
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of RIP1 kinase: a patent review (2016-present).
Harris PA
Expert Opin Ther Pat; 2021 Feb; 31(2):137-151. PubMed ID: 33249869
[No Abstract] [Full Text] [Related]
14. State-of-the-art of small molecule inhibitors of the TAM family: the point of view of the chemist.
Baladi T; Abet V; Piguel S
Eur J Med Chem; 2015 Nov; 105():220-37. PubMed ID: 26498569
[TBL] [Abstract][Full Text] [Related]
15. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
16. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome.
Ren Y; Su Y; Sun L; He S; Meng L; Liao D; Liu X; Ma Y; Liu C; Li S; Ruan H; Lei X; Wang X; Zhang Z
J Med Chem; 2017 Feb; 60(3):972-986. PubMed ID: 27992216
[TBL] [Abstract][Full Text] [Related]
18. 1,5-Dihydro-benzo[e][1,4]oxazepin-2(1H)-ones containing a 7-(5'-cyanopyrrol-2-yl) group as nonsteroidal progesterone receptor modulators.
Kern JC; Terefenko EA; Fensome A; Unwalla R; Wrobel J; Cohen J; Zhu Y; Berrodin TJ; Yudt MR; Winneker RC; Zhang Z; Zhang P
Bioorg Med Chem Lett; 2008 Sep; 18(18):5015-7. PubMed ID: 18722119
[TBL] [Abstract][Full Text] [Related]
19. Protocols for the Design of Kinase-focused Compound Libraries.
Jacoby E; Wroblowski B; Buyck C; Neefs JM; Meyer C; Cummings MD; van Vlijmen H
Mol Inform; 2018 May; 37(5):e1700119. PubMed ID: 29116686
[TBL] [Abstract][Full Text] [Related]
20. Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.
Li Y; Xiong Y; Zhang G; Zhang L; Yang W; Yang J; Huang L; Qiao Z; Miao Z; Lin G; Sun Q; Niu T; Chen L; Niu D; Li L; Yang S
J Med Chem; 2018 Dec; 61(24):11398-11414. PubMed ID: 30480444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
